Small molecule · Antagonist of endothelin B receptor (EDNRB)
Phase 2Most advanced trial
1Registered trials
What is Vodudeutentan?
Vodudeutentan is an antagonist of the endothelin B receptor (ETBR, EDNRB), a G-protein coupled receptor overexpressed on many tumor cell types. It binds ETBR on tumor cells, blocking ETBR-mediated signaling that supports proliferation, invasion and immunosuppression. It is studied in ovarian cancer.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.